Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John R Nelson

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Postgraduate Medicine|October 5, 2017
Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?John R Nelson, Wayne S True, Viet Le, et al.
American Heart Journal Plus : Cardiology Research and Practice|April 1, 2024
Differentiating EPA from EPA/DHA in cardiovascular risk reductionPeter P Toth, M John Chapman, Klaus G Parhofer, et al.
Journal of the American Chemical Society|February 24, 2005
Terminal phosphate-labeled nucleotides with improved substrate properties for homogeneous nucleic acid assaysAnup Sood, Shiv Kumar, Satyam Nampalli, et al.
The Cochrane Database of Systematic Reviews|April 25, 2025
Interventions for preventing diarrhoea-associated haemolytic uraemic syndromeAamer Imdad, John R Nelson, Emily E Tanner-Smith, et al.
Clinical Cardiology|January 25, 2018
Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE studyMatthew Budoff, J Brent Muhlestein, Viet T Le, et al.
Journal of Medical Economics|June 29, 2016
A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United StatesSephy Philip, Sumita Chowdhury, John R Nelson, et al.
Cardiovascular Diabetology|January 23, 2025
Atherogenic index of plasma and coronary artery disease: a systematic review and meta-analysis of observational studiesRamin Assempoor, Mohammad Shahabaddin Daneshvar, Aryan Taghvaei, et al.
Journal of Clinical Lipidology|February 5, 2022
Plasma fatty acid profiles: Relationships with sex, age, and state-reported heart disease mortality rates in the United StatesMargaret R Diffenderfer, Nandani Rajapakse, Ericka Pham, et al.
Postgraduate Medicine|April 26, 2021
EPA's pleiotropic mechanisms of action: a narrative reviewJohn R Nelson, Matthew J Budoff, Omar R Wani, et al.
Acta Cardiologica|August 12, 2025
Effects of purified eicosapentaenoic acid versus mixed eicosapentaenoic/docosahexaenoic acid pharmacotherapies on coronary plaque volume: network meta-analysis of prospective coronary imaging trialsJohn P Sheppard, Suvasini Lakshmanan, Leonard Palatnic, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Postgraduate Medicine|October 5, 2017
Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?John R Nelson, Wayne S True, Viet Le, et al.
American Heart Journal Plus : Cardiology Research and Practice|April 1, 2024
Differentiating EPA from EPA/DHA in cardiovascular risk reductionPeter P Toth, M John Chapman, Klaus G Parhofer, et al.
Journal of the American Chemical Society|February 24, 2005
Terminal phosphate-labeled nucleotides with improved substrate properties for homogeneous nucleic acid assaysAnup Sood, Shiv Kumar, Satyam Nampalli, et al.
The Cochrane Database of Systematic Reviews|April 25, 2025
Interventions for preventing diarrhoea-associated haemolytic uraemic syndromeAamer Imdad, John R Nelson, Emily E Tanner-Smith, et al.
Clinical Cardiology|January 25, 2018
Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE studyMatthew Budoff, J Brent Muhlestein, Viet T Le, et al.
Journal of Medical Economics|June 29, 2016
A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United StatesSephy Philip, Sumita Chowdhury, John R Nelson, et al.
Cardiovascular Diabetology|January 23, 2025
Atherogenic index of plasma and coronary artery disease: a systematic review and meta-analysis of observational studiesRamin Assempoor, Mohammad Shahabaddin Daneshvar, Aryan Taghvaei, et al.
Journal of Clinical Lipidology|February 5, 2022
Plasma fatty acid profiles: Relationships with sex, age, and state-reported heart disease mortality rates in the United StatesMargaret R Diffenderfer, Nandani Rajapakse, Ericka Pham, et al.
Postgraduate Medicine|April 26, 2021
EPA's pleiotropic mechanisms of action: a narrative reviewJohn R Nelson, Matthew J Budoff, Omar R Wani, et al.
Acta Cardiologica|August 12, 2025
Effects of purified eicosapentaenoic acid versus mixed eicosapentaenoic/docosahexaenoic acid pharmacotherapies on coronary plaque volume: network meta-analysis of prospective coronary imaging trialsJohn P Sheppard, Suvasini Lakshmanan, Leonard Palatnic, et al.
Pageof 5